

Medtronic to Unveil Pivotal Trial Results for Hybrid Closed Loop System at American Diabetes Association 2016 Meeting

June 7, 2016 8:00 AM CT

Medtronic

DUBLIN - June 7, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the 76th Scientific Sessions of the American Diabetes Association in New Orleans. Among the presentations are late breaking pivotal trial results of the Hybrid Closed Loop system, pivotal trial results for the company's fourth generation sensor and further study of the company's SmartGuard(TM) technology. Hybrid Closed Loop system is approved for investigational use only in the U.S., and many devices being presented at ADA are also investigational use only.

"At ADA 2016, we have a number of important data presentations about our marketed products and key products in our pipeline, most notably our Hybrid Closed Loop system and next generation sensor," said Francine R. Kaufman, M.D., chief medical officer and vice president of global, clinical and medical affairs for Medtronic Diabetes. "We are proud to be the first company to present results of a pivotal trial of a closed loop system, which is designed to automatically control glucose levels 24 hours a day with less input from patients, as we continue toward our goal of helping people with diabetes enjoy greater freedom and better health."

"The ability for people with diabetes to achieve better glucose control and live longer, healthier lives has significantly improved with insulin pumps and continuous glucose monitoring systems. However, patients must still make frequent decisions each day while using today's systems," said Richard M. Bergenstal, M.D., of the International Diabetes Center in Minneapolis. "Simplifying this self-management and adding a little peace of mind with this more automated Hybrid Closed Loop system would impact these patients' lives in a very meaningful way."

Scientific Presentations

Closing the Loop

- "[Pivotal Trial of a Hybrid Closed-Loop System in Type 1 Diabetes \(T1D\)](#)" will be moderated by Dr. Richard Bergenstal on Sunday, June 12 from noon to 2 p.m. 99-LB.
- "[Overnight Closed-Loop \(OCL\) at Home Compared with Sensor-Augmented Pump with Low-Glucose Suspend \(SAP-LGS\) Improves Time in Target Range in Adults and Reduces Hypoglycemia in Adolescents](#)" will be presented by Dr. Amin Sharifi on Saturday, June 11 from 8:15-8:30 a.m. 78-OR.
- "[Quantitative Evaluation of a Predictive Low-Glucose Management \(PLGM\) System](#)" will be presented by Dr. Bruce Buckingham on Saturday, June 11 at 9:30-9:45 a.m. 83-OR.
- "[Glucose Concentrations and Rates of Change during Hypoglycemia Induction to Evaluate a Predictive Low Glucose Management \(PLGM\) System](#)" will be moderated by Dr. Satish Garg on Saturday, June 11 from 11:30 a.m. to 12:30 p.m. and Sunday, June 12 from noon to 2 p.m. 985-P.
- "[Incremental Benefits of Predictive vs. Responsive Low Glucose Suspension Strategies in Automated Insulin Delivery Systems](#)" will be moderated by Dr. Chantal McMahon on Sunday, June 12 from noon to 2 p.m. 998-P.
- "[Hypoglycemia Reduction in Sensor-Augmented Pump Therapy \(SAP\) with Predictive Low Glucose Management \(SmartGuard\(TM\)\) in Children with Type 1 Diabetes](#)" will be moderated by Dr. Olga Kordonouri on Monday, June 13 from noon to 1 p.m. 871-P.

Sensing

The conference will showcase advancements of Medtronic continuous glucose monitoring (CGM) technology with intelligent diagnostics and sensor redundancy, resulting in market-leading accuracy, usability and reliability for both stand-alone and closed-loop CGM systems.

- "[Accuracy of a Fourth-Generation Glucose Sensor at Different Anatomical Locations](#)" will be moderated by Dr. Bruce Bode on Sunday, June 12 from noon to 2 p.m. 879-P.
- "[Accuracy of a Fourth-Generation Glucose Sensor Throughout its Functional Life](#)" will be moderated by Dr. Ronald Brazg on Sunday, June 12 from noon to 2 p.m. 897-P.
- "[Accuracy of a Fourth-Generation Glucose Sensor Paired with Different Real-Time Display Devices](#)" will be moderated by Dr. Mark Christiansen on Sunday, June 12 from noon to 2 p.m. 901-P.
- "[Fourth-Generation Glucose Sensor for Use in Standalone CGM and Sensor Augmented Pump Systems](#)" will be presented by Ashley Sullivan on Sunday, June 12 from noon to 2 p.m. 916-P.
- "[Fifth-Generation Glucose Sensor System with Extended Wear and Fewer Calibrations](#)" will be moderated by Dr. Johanna Ulloa on Sunday, June 12 from noon to 2 p.m. 905-P.

Health Economics

- "[Inpatient Costs and Utilizations among Type 1 Diabetes Patients Treated with Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections](#)" will be moderated by Dr. Janice Chung on Sunday, June 12 from noon to 2 p.m. 1243-P.

Type 2 Diabetes

- "[Sensor-Augmented Pumps vs. Multiple Daily Injections for Achieving Glycemic Goals in Hospitalized Patients with Type 2 Diabetes in China](#)" will be presented by Dr. Weijun Gu from 5:30-5:45 p.m. on Friday, June 10. 18-OR.

Company Presentations

Medtronic will host a series of presentations at Booth #301 from Saturday through Monday, where the audience will get the opportunity to hear from experts regarding the application of Medtronic technologies in their practice.

- Transforming Data into Actions with Personalized Diabetes Insights: Saturday, June 11 at 10:30 a.m.; Sunday, June 12 at 3 p.m.; Monday, June 13 at 1 p.m.
- Advances in the Use of iPro2 in Type 2 Diabetes: Saturday, June 11 at 1 p.m. and Sunday, June 12 at 1:30 p.m.
- Improving Outcomes Through Automation with SmartGuard Technology: Saturday, June 11 at 3 p.m.; Sunday, June 12 at 10:30 a.m.; Monday, June 13 at 10:30 a.m.

Analyst and Investor Briefing

Medtronic will host a webcast to provide an update on its Diabetes Group during the conference on Sunday, June 12 from 2 p.m. to approximately 4 p.m. CDT. The webcast will feature remarks from Medtronic management, including comments on Medtronic's clinical data, product pipelines, and market outlooks. The live audio webcast can be accessed at <http://investorrelations.medtronic.com> on June 12. Within 24 hours of the webcast, a replay will be available by clicking on the Investor Events link at <http://investorrelations.medtronic.com>. This event is not part of the official ADA Scientific Sessions.

About the Diabetes Group at Medtronic (www.medtronicdiabetes.com)

Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

Contacts:

Pamela Reese
Public Relations
+1-818-576-3398

Ryan Weispfenning
Investor Relations
+1-763-505-4626

HUG#2018380